Updated:
Ferrer Freeman & Co
Carlos Ferrer and David Freeman founded Ferrer Freeman & Co in 1995 after careers at GE Capital's equity unit.
Ferrer Freeman & Co
Carlos Ferrer and David Freeman founded Ferrer Freeman & Co in 1995 after careers at GE Capital's equity unit. The firm set up in Greenwich, Connecticut with a deliberate mandate: invest only in healthcare. That constraint was unusual for the mid-1990s, when most middle-market private equity firms ran generalist portfolios. The founders structured the firm as a partnership that would concentrate capital, operational energy, and sector relationships into one vertical. FFC pursues growth equity and buyout investments in commercial-stage healthcare companies across three sub-sectors: healthcare services, medical devices, and specialty pharmaceuticals. The firm typically writes equity checks of $15 million to $50 million per deal, targeting companies with $5 million to $50 million in revenue. Portfolio positions have historically included companies in outsourced pharmaceutical services, ambulatory surgery centers, specialty physician practice management, and diagnostic imaging. The firm exited several portfolio companies through strategic sales to larger healthcare consolidators, a pattern consistent with its focus on building platforms attractive to strategic acquirers. FFC closed its fourth fund, Ferrer Freeman & Co IV, in 2006, at roughly the same scale as prior vehicles. The firm continued managing its portfolio through the late 2000s and 2010s, largely harvesting existing investments rather than deploying fresh capital. Public record indicates no new fund closes after Fund IV. In September 2013, the firm realized a significant exit when portfolio company Medpace, a clinical research organization, completed its initial public offering on the Nasdaq — a transaction that marked the maturation of an investment held for nearly a decade. FFC illustrates a mid-market private equity model that bet entirely on sector specialization before it became standard industry practice. Unlike generalist firms that later added healthcare-dedicated teams, FFC was born into the constraint. The firm's partnership structure survived the departure of founding capital sources and the structural shift from GE-linked origins to independent institutional fundraising. Its post-deployment posture — managing legacy assets without successive fundraises — matches a pattern of founder-led firms that wind down investment activity but maintain fiduciary responsibility for remaining portfolio companies.
General information
Firm type
Asset Manager
Year founded
1995
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Greenwich
Corporate office
Greenwich, CT, United States
Principals
Carlos Ferrer
Co-Founder & Managing Partner
David Freeman
Co-Founder & Managing Partner
Sector focus
Frequently asked questions
Why does Ferrer Freeman & Co invest exclusively in healthcare?
Co-founders Carlos Ferrer and David Freeman established the firm in 1995 with a singular healthcare mandate. Both had investment backgrounds at GE Capital, where they likely developed the conviction that deep sector expertise produces better outcomes than generalist approaches. The firm has maintained that focus across all four of its funds, targeting healthcare services, medical devices, and specialty pharmaceuticals. This consistency is unusual for a firm founded in the mid-1990s, when most middle-market private equity firms diversified across industries.
What is FFC's current investment status?
Ferrer Freeman & Co closed its last fund — Ferrer Freeman & Co IV — in 2006 and has not raised a subsequent vehicle. The firm has spent the years since managing and exiting its existing portfolio investments. The most notable public exit was the September 2013 IPO of Medpace, a clinical research organization (per SEC filings). The firm's current posture reflects a harvest-and-return-capital phase common among founder-led partnerships that do not transition to a next generation of fundraising.
What types of healthcare companies does Ferrer Freeman target?
FFC invests across three healthcare sub-sectors: healthcare services, medical devices, and specialty pharmaceuticals. Within healthcare services, the firm has backed companies in physician practice management, ambulatory surgery, diagnostic imaging, and outsourced pharmaceutical services. The firm targets commercial-stage businesses with $5 million to $50 million in revenue, typically writing equity checks between $15 million and $50 million per investment. The model builds platforms intended for eventual sale to strategic healthcare consolidators.
How is Ferrer Freeman & Co structured?
Ferrer Freeman & Co is structured as a traditional middle-market private equity partnership led by its two original co-founders, Carlos Ferrer and David Freeman. The firm raised four institutional funds from limited partners over its active fundraising period, then transitioned into portfolio management without raising additional capital. This structure stands apart from both single-family offices (which manage proprietary capital) and larger institutional platforms that pursue continuous fundraising cycles.
Who are the key decision-makers at Ferrer Freeman & Co?
Investment decisions at Ferrer Freeman & Co have historically rested with co-founders Carlos Ferrer and David Freeman, who hold the titles of Managing Partner. Both originated from GE Capital's equity investment unit before launching FFC in 1995. The partnership has operated with a lean team structure consistent with its middle-market focus and sector-specialist mandate. No significant departures or additions of named investment partners have been publicly recorded.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: